Search the Newsreel

Vertex (VRTX) Stock Looks Above Fair Value On Earnings Yet About Right Overall

Vertex Pharmaceuticals (VRTX) has seen strong multi-year performance, with a 158.2% return over the past five years, but its current valuation suggests it's neither a clear bargain nor obviously overvalued. The stock trades at 29.1x earnings, slightly above Simply Wall St's fair P/E estimate …

Is Vertex Pharmaceuticals (VRTX) Fairly Valued As Pipeline Catalysts Near?

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Vertex Pharmaceuticals stock has delivered a strong 5 year return, yet current checks suggest the market now prices it roughly in line with its fundamentals rather than …

Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors

Vertex Pharmaceuticals Inc. (VRTX) stock fell 2.07% on Friday, closing at $505.75, amid a general market decline where the S&P 500 and Dow Jones Industrial Average also saw losses. This marked the third consecutive day of losses for the company's shares.

Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More

The past couple of years have been volatile for Vertex Pharmaceuticals (NASDAQ: VRTX). Between clinical setbacks and worse-than-expected financial results, the company has sometimes disappointed investors. However, Vertex has always bounced back, and it recently hit a new all-time high, though it has since …

Vertex Pharmaceuticals (VRTX) Could Be 8% Undervalued Following Raised 2026 Guidance

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Vertex Pharmaceuticals (VRTX) has drawn fresh attention after reporting second quarter 2026 results, raising full year revenue guidance to US$13.1b to US$13.2b, and completing …

Vertex Pharmaceuticals: I Was Wrong About Its Near-Term Prospects (Rating Upgrade)

Crinetics Pharmaceuticals merger with Vertex Pharmaceuticals advances after regulatory clearances

The proposed merger between Crinetics Pharmaceuticals (NASDAQ:CRNX) and Vertex Pharmaceuticals (NASDAQ:VRTX) has progressed after securing regulatory clearances, including the expiration of the Hart-Scott-Rodino Antitrust Improvements Act waiting period and approvals in Austria, Germany, and Australia. The acquisition, valued at approximately $10 billion, is expected …

Vertex to acquire Crinetics after HSR clearance; closing expected early Sept

Crinetics Pharmaceuticals announced that it has received HSR clearance for its merger with Vertex. The HSR waiting period expired on August 12, 2026, and antitrust approvals have also been secured in Austria, Germany, and Australia. The merger's closing is targeted for early September 2026, …

Crinetics Pharmaceuticals (CRNX) advances Vertex merger after key antitrust milestones

Crinetics Pharmaceuticals announced significant progress in its planned acquisition by Vertex Pharmaceuticals, with the Hart-Scott-Rodino waiting period expiring and antitrust approvals secured in Austria, Germany, and Australia. The merger's completion hinges on Crinetics shareholder approval at a meeting on August 28, 2026, with an …

Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors

Vertex Pharmaceuticals Inc. (VRTX) saw its stock decline by 1.77% on Thursday, closing at $516.44. This underperformance occurred despite a generally favorable trading day for the broader market, with both the S&P 500 and Dow Jones Industrial Average posting gains. This marks the second …

Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says

Vertex Pharmaceuticals (VRTX) has multiple potential catalysts coming from its portfolio that provide a net positive risk-reward profile for the company, RBC Capital Markets said in a Wednesday note.The company is expected to present results from its phase 1 study of VX-828 in Silver …

Scotiabank Remains a Buy on Vertex Pharmaceuticals (VRTX)

5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q2 Earnings Call

5 Insightful Analyst Questions From Vertex Pharmaceuticals's Q2 Earnings Call Vertex Pharmaceuticals' second quarter reflected strong commercial momentum, with management highlighting the performance of its cystic fibrosis (CF) portfolio and accelerating uptake of newer products like CASGEVY and JOURNAVX. CEO Reshma Kewalramani attributed revenue …

Crinetics Pharmaceuticals stock hits all-time high at 84.35 USD By Investing.com

Crinetics Pharmaceuticals (CRNX) stock reached an all-time high of $84.35, currently trading 1% below its 52-week high, with a market capitalization of $8.94 billion. The stock has seen a 196.14% increase over the past year, or 207% according to InvestingPro data, though its RSI …

Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and MoonLake Immunotherapeutics (MLTX)

Two analysts have issued bullish sentiments on healthcare companies, Vertex Pharmaceuticals (VRTX) and MoonLake Immunotherapeutics (MLTX). William Blair analyst Myles Minter reiterated a Buy rating on Vertex with a price target suggesting a 3.7% upside, while LifeSci Capital analyst Rami Katkhuda maintained a Buy …

VERTEX PHARMACEUTICALS INCORPORATED : BOFA GLOBAL RESEARCH ADDS STOCK TO ITS US 1 LIST

BofA Global Research has added Vertex Pharmaceuticals Inc. (VRTX.O) to its US 1 List. The article, sourced from Reuters, states this financial update regarding the pharmaceutical company. It also includes a disclaimer that the content reflects the author's opinion and is not investment advice.

Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Handelsbanken Fonder AB

Handelsbanken Fonder AB reduced its stake in Vertex Pharmaceuticals (NASDAQ:VRTX) by 1.2% in the second quarter, selling 2,555 shares. Despite this, institutional investors collectively own 90.96% of the company, and Wall Street analysts maintain a "Moderate Buy" consensus rating with an average price target …

Vertex Pharma stock added to BofA US 1 list of top ideas

Bank of America has added Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) to its US 1 List, highlighting it as a top investment idea. The biotechnology company, with a market cap of $132.79 billion, has shown strong year-to-date and annual performance, despite being considered overvalued by InvestingPro. …

Vertex Pharmaceuticals (VRTX) legt um 11,3 % zu, nachdem das Unternehmen seine Umsatzprognose für 2026 angehoben und den Ausblick für den Cashflow angepasst hat – Hat sich das bullische Szenario geändert?

Vertex Pharmaceuticals (VRTX) sube un 11,3 % tras elevar sus previsiones de ingresos para 2026 y revisar al alza sus perspectivas de flujo de caja: ¿ha cambiado el panorama alcista?

Vertex Pharmaceuticals (VRTX) Is Up 11.3% After Raising 2026 Revenue Guidance And CF Outlook Shift – Has The Bull Case Changed?

Vertex Pharmaceuticals reported strong Q2 2026 results, raising its full-year 2026 revenue guidance to US$13.1 billion to US$13.2 billion and benefiting from reduced competition in cystic fibrosis. The company also entered a collaboration with AbCellera Biologics to expand its portfolio beyond CF into areas …

VERTEX PHARMACEUTICALS INCORPORATED : JEFFERIES RAISES TARGET PRICE TO $633 FROM $610

Jefferies has raised its target price for VERTEX PHARMACEUTICALS INCORPORATED (VRTX.O) to $633 from $610. The article, published by Reuters, indicates this adjustment in the target price for the pharmaceutical company's stock. It also includes a disclaimer stating that the content reflects the author's …

Vertex Pharmaceuticals Rose 7% Today. Here’s Where the Stock Is Headed in 2026

Wall Street Analysts Are Neutral on Top Healthcare Picks

Wall Street analysts have issued neutral ratings for Vertex Pharmaceuticals (VRTX) and Travere Therapeutics (TVTX), indicating that experts are neither bullish nor bearish on these healthcare stocks. Stifel Nicolaus analysts maintained Hold ratings for both companies, with specific price targets set. Despite these neutral …

Vertex Stock Jumps 5.9% as Rival Cystic Fibrosis Drug Fails

Vertex Pharmaceuticals (VRTX) stock rose 5.9% after a rival cystic fibrosis drug, SION-719 from Sionna Therapeutics, failed to meet its primary endpoint in a Phase 2a trial. This development solidifies Vertex's dominant position in the cystic fibrosis market. Despite the stock jump, Vertex's valuation …

Vertex Pharmaceuticals Jumps 6.7% After Truist Securities Maintains Buy

Vertex Pharmaceuticals (VRTX) saw its stock price jump 6.7% after five Wall Street firms either upgraded their ratings or increased price targets. The coordinated analyst action, with an average new price target of $554, indicates strengthening investor confidence in the biotechnology company. Investors are …

Vertex Pharmaceuticals (VRTX) Is Up 5.4% After Raising 2026 Revenue Guidance And Expanding Its Pipeline - Has The Bull Case Changed?

Vertex Pharmaceuticals recently reported second-quarter 2026 results, with revenue rising to US$3,333.9 million and net income reaching US$1,099.8 million, and raised its full-year 2026 revenue guidance to US$13.10–US$13.20 billion. At the same time, a new collaboration with AbCellera on multispecific T‑cell engagers and a …

Sionna’s cystic fibrosis failure is a windfall for Vertex’s blockbuster franchise

Sionna Therapeutics' shares plummeted over 90% after its cystic fibrosis drug candidate, SION-719, failed a Phase 2a clinical trial. The failure of SION-719, intended as an add-on to Vertex Pharmaceuticals' Trikafta, reinforces Vertex's dominant position in the cystic fibrosis market, causing Vertex's shares to …

Weekly Recap: Vertex $10B deal, guidance paused and Q2 loss — Crinetics

Crinetics Pharmaceuticals (CRNX) is being acquired by Vertex for approximately $10 billion. As a result, CRNX has paused its financial guidance despite reporting $25.1 million in Q2 2026 revenue and a $120.9 million net loss. Vertex, meanwhile, has raised its 2026 outlook and plans …

Vertex Pharmaceuticals Inc Stock (VRTX) Opened Up by 9.76% on Aug 10: What Investors Need To Know

Vertex Pharmaceuticals Inc (VRTX) stock surged by 9.76% on August 10th following positive Phase 3 data for its non-opioid pain treatment and an upward revision of its full-year revenue guidance. The company outperformed its sector, attracting institutional capital and benefiting from a broader resurgence …

Vertex Pharmaceuticals stock hits all-time high at 539.99 USD

Vertex Pharmaceuticals Inc. (VRTX) stock reached an all-time high of $539.99, currently trading at $543.41, reflecting a 35% increase over the past year. Despite its strong performance and $125.7 billion market cap, an InvestingPro analysis suggests the stock might be overvalued relative to its …

Why Vertex Pharma Popped, As A Key Rival Plummeted 90%

Vertex stock surged Monday after its competitor, Sionna Therapeutics, missed the mark for its highly anticipated cystic fibrosis treatment. Continue Reading

Sionna’s experimental cystic fibrosis pill falls flat in mid-stage trial

Sionna Therapeutics announced that its experimental cystic fibrosis pill, SION-719, failed to show any additional benefit when used as an add-on therapy to Vertex Pharmaceuticals’ Trikafta in a Phase 2 trial. The company will discontinue the drug's development as an add-on and plans to …